Differences in the Phenotype, Cytokine Gene Expression Profiles, and In Vivo Alloreactivity of T Cells Mobilized with Plerixafor Compared with G-CSF

Plerixafor (Mozobil) is a CXCR4 antagonist that rapidly mobilizes CD34+ cells into circulation. Recently, plerixafor has been used as a single agent to mobilize peripheral blood stem cells for allogeneic hematopoietic cell transplantation. Although G-CSF mobilization is known to alter the phenotype and cytokine polarization of transplanted T cells, the effects of plerixafor mobilization on T cells have not been well characterized. In this study, we show that alterations in the T cell phenotype and cytokine gene expression profiles characteristic of G-CSF mobilization do not occur after mobilization with plerixafor. Compared with nonmobilized T cells, plerixafor-mobilized T cells had similar phenotype, mixed lymphocyte reactivity, and Foxp3 gene expression levels in CD4+ T cells, and did not undergo a change in expression levels of 84 genes associated with Th1/Th2/Th3 pathways. In contrast with plerixafor, G-CSF mobilization decreased CD62L expression on both CD4 and CD8+ T cells and altered expression levels of 16 cytokine-associated genes in CD3+ T cells. To assess the clinical relevance of these findings, we explored a murine model of graft-versus-host disease in which transplant recipients received plerixafor or G-CSF mobilized allograft from MHC-matched, minor histocompatibility–mismatched donors; recipients of plerixafor mobilized peripheral blood stem cells had a significantly higher incidence of skin graft-versus-host disease compared with mice receiving G-CSF mobilized transplants (100 versus 50%, respectively, p = 0.02). These preclinical data show plerixafor, in contrast with G-CSF, does not alter the phenotype and cytokine polarization of T cells, which raises the possibility that T cell–mediated immune sequelae of allogeneic transplantation in humans may differ when donor allografts are mobilized with plerixafor compared with G-CSF.

[1]  I. Choi,et al.  G-CSF-treated donor CD4+ T cells attenuate acute GVHD through a reduction in Th17 cell differentiation. , 2012, Cytokine.

[2]  E. Healy,et al.  CD70-CD27 interaction augments CD8+ T-cell activation by human epidermal Langerhans cells. , 2012, The Journal of investigative dermatology.

[3]  B. Falini,et al.  Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. , 2011, Blood.

[4]  R. Vij,et al.  Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. , 2008, Blood.

[5]  G. Ehninger,et al.  The Graft Content of Donor T Cells Expressing γδTCR+ and CD4+foxp3+ Predicts the Risk of Acute Graft versus Host Disease after Transplantation of Allogeneic Peripheral Blood Stem Cells from Unrelated Donors , 2007, Clinical Cancer Research.

[6]  D. Nachbaur,et al.  Regulatory T-Cells in the Graft and the Risk of Acute Graft-Versus-Host Disease After Allogeneic Stem Cell Transplantation , 2007, Transplantation.

[7]  J. P. McCoy,et al.  Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors. , 2007, Blood.

[8]  J. Ring,et al.  Fox‐P3‐positive regulatory T cells are present in the skin of generalized atopic eczema patients and are not particularly affected by medium‐dose UVA1 therapy , 2007, Photodermatology, photoimmunology & photomedicine.

[9]  K. Rezvani,et al.  High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. , 2006, Blood.

[10]  C. Dunbar,et al.  AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. , 2006, Blood.

[11]  J. Ritz,et al.  Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. , 2005, Blood.

[12]  D. Link,et al.  A pilot study evaluating the safety and efficacy of AMD3100 for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells in patients with advanced hematological malignancies , 2005 .

[13]  C. Thoburn,et al.  Association of Foxp3 regulatory gene expression with graft-versus-host disease. , 2004, Blood.

[14]  B. Wood,et al.  Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. , 2003, Blood.

[15]  C. Fathman,et al.  CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation , 2003, Nature Medicine.

[16]  Bernd Hertenstein,et al.  G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases. , 2003, Blood.

[17]  M. Shlomchik,et al.  Memory CD4+ T cells do not induce graft-versus-host disease. , 2003, The Journal of clinical investigation.

[18]  S. Leitman,et al.  Analysis of PBPC cell yields during large‐volume leukapheresis of subjects with a poor mobilization response to filgrastim , 2003, Transfusion.

[19]  E. De Clercq,et al.  Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4 , 2002, FEBS letters.

[20]  T. Panzarella,et al.  A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. , 2002, Blood.

[21]  John D. Storey.  A direct approach to false discovery rates , 2002 .

[22]  N. Russell,et al.  Peripheral blood stem cell harvests from G-CSF-stimulated donors contain a skewed Th2 CD4 phenotype and a predominance of type 2 dendritic cells. , 2002, Experimental hematology.

[23]  J. Tisdale,et al.  Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait. , 2002, Blood.

[24]  C. Hillyer.  Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives In patients with hematologic cancers , 2001 .

[25]  A. Nagler,et al.  Rapid and efficient homing of human CD34(+)CD38(-/low)CXCR4(+) stem and progenitor cells to the bone marrow and spleen of NOD/SCID and NOD/SCID/B2m(null) mice. , 2001, Blood.

[26]  R Storb,et al.  Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. , 2001, The New England journal of medicine.

[27]  V. Diehl,et al.  Increase of anti-inflammatory cytokines in patients with esophageal cancer after perioperative treatment with G-CSF. , 2000, Cytokine.

[28]  T. Schumacher,et al.  CD27 is required for generation and long-term maintenance of T cell immunity , 2000, Nature Immunology.

[29]  N. Schmitz,et al.  Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). , 2000, Blood.

[30]  S. Singhal,et al.  Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial , 2000, The Lancet.

[31]  O. Ilhan,et al.  Soluble adhesion molecules (sICAM-1, sL-Selectin, sE-Selectin, sCD44) in healthy allogenic peripheral stem-cell donors primed with recombinant G-CSF. , 2000, Cytotherapy.

[32]  N. Young,et al.  Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. , 2000, Blood.

[33]  J. Bourhis,et al.  Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  E. Wang,et al.  Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. , 1999, Journal of immunology.

[35]  E. Montserrat,et al.  Efficacy and toxicity of a high-dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors , 1999, Bone Marrow Transplantation.

[36]  R. Alon,et al.  Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. , 1999, Science.

[37]  F. Aranha,et al.  A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies , 1998, Bone Marrow Transplantation.

[38]  E. De Clercq,et al.  Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. , 1997, Antiviral research.

[39]  M. Mielcarek,et al.  Phenotype and engraftment potential of cytokine‐mobilized peripheral blood mononuclear cells , 1997, Current opinion in hematology.

[40]  K. Matsushima,et al.  IL‐8 induces T cell Chemotaxis, suppresses IL‐4, and up‐regulates IL‐8 production by CD4+ T cells , 1996, Journal of leukocyte biology.

[41]  J. Ferrara,et al.  Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. , 1995, Blood.

[42]  T. Hartung,et al.  Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. , 1995, Blood.

[43]  Gary A. Churchill,et al.  Estimating p-values in small microarray experiments , 2007, Bioinform..

[44]  S. Nakao,et al.  Administration of G-CSF to normal individuals diminishes L-selectin+ T cells in the peripheral blood that respond better to alloantigen stimulation than L-selectin− T cells , 1999, Bone Marrow Transplantation.